Head & Neck Cancers | Specialty

Rolling Submission for Toripalimab Started for Nasopharyngeal Carcinoma

March 4th 2021

The filing of a biologics license application has been initiated with the FDA for toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma.

FDA Grants Breakthrough Therapy Designation to Tipifarnib for HRAS-Mutated HNSCC

February 24th 2021

February 24, 2021 - The FDA has granted a breakthrough therapy designation to tipifarnib for use in patients with recurrent or metastatic HRAS-mutated head and neck squamous cell carcinoma with variant allele frequency of 20% or higher following progressive disease on platinum-based chemotherapy.

Investigators Aim Novel T-Cell Therapy at Solid Tumor Target

February 23rd 2021

ADP-A2M4CD8, a novel T-cell therapy, is being investigated in a range of tumor types that express MAGEA4, an antigen expressed in solid tumors that investigators say represents a promising target for cellular immunotherapy.

Frontline Durvalumab Fails to Improve OS in Recurrent or Metastatic HNSCC

February 5th 2021

February 5, 2021 - Durvalumab failed to improve overall survival over the EXTREME chemotherapy regimen in the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with tumors expressed high levels of PD-L1, missing a primary end point of the phase 3 KESTREL trial.

Search Continues for Agents to Provide Additive Benefit to Chemoradiation in Head and Neck Cancer

January 21st 2021

Nabil F. Saba, MD, FACP, discusses the results of the JAVELIN Head and Neck 100 trial, as well as data from other key, recent studies in head and neck cancer.

28-Gene Score May Predict Distant Metastatic Recurrence in Advanced Head and Neck Cancers

January 18th 2021

Although the ability to treat head and neck cancer has certainly improved over the years, a significant percentage of patients experience recurrent disease after initial treatment.

NICE Rejects Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

January 8th 2021

January 8th, 2021 - The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against nivolumab for use in patients with recurrent or metastatic head and neck squamous cell carcinoma who experienced disease progression during or after platinum-based chemotherapy.

Lindau on Leading Successful Surgical Fellowships

December 31st 2020

In our exclusive interview, Robert Lindau, III, MD, discusses his journey into the head and neck surgery space, tips for a successful fellowship, and the importance of creating a family-like environment within the fellowship program he directs.

SGX942 Shows Meaningful Reduction in Oral Mucositis in Head and Neck Cancer, But Not Statistically Significant

December 23rd 2020

December 23, 2020 — Although SGX942 was found to induce clinically meaningful reductions in severe oral mucositis vs placebo in patients with head and neck cancer, the benefit failed to reach statistical significance, thus missing the primary end point of the phase 3 DOM-INNATE study.

Cabozantinib Significantly Improves PFS in Previously Treated, Radioiodine-Refractory Differentiated Thyroid Cancer

December 21st 2020

December 21, 2020 - Cabozantinib was found to significantly improve progression-free survival compared with placebo in patients with dedifferentiated thyroid cancer who are refractory to radioiodine and have progressed following up to 2 prior VEGF-targeted treatments.

x